On July 10, 2019, President Trump and the United States Department of Health and Human
Services announced the Advancing American Kidney Health initiative (Table 1). This
executive order outlines 3 principal goals and 7 objectives (Table 2). These goals
and objectives are comprehensive and well conceived, and if acted upon, they would
do much to reduce the tremendous health burdens and costs associated with chronic
kidney disease (CKD) and end-stage renal disease (ESRD) in the United States. These
goals are accompanied by ambitious specific targets, including a 25% reduction in
the number of Americans who develop ESRD by 2030, initiation of home dialysis or transplantation
for 80% of new patients with ESRD by 2025, and doubling the number of kidneys available
for transplantation by 2030.
Table 1
Links to additional information elaborating on the Advancing American Kidney Health
initiative
Link
1
Advancing American Kidney Health executive order: https://www.whitehouse.gov/presidential-actions/executive-order-advancing-american-kidney-health/.
Accessed August 28, 2019.
2
Report by the Health and Human Services Assistant Secretary for Planning and Evaluation:
https://aspe.hhs.gov/system/files/pdf/262046/AdvancingAmericanKidneyHealth.pdf. Accessed
August 28, 2019.
3
Centers for Medicare and Medicaid Innovation ESRD Treatment Choices Model Web site:
https://innovation.cms.gov/initiatives/esrd-treatment-choices-model/. Accessed August
28, 2019.
4
Centers for Medicare and Medicaid Innovation Voluntary Kidney Models Web site: https://innovation.cms.gov/initiatives/voluntary-kidney-models/.
Accessed August 28, 2019.
5
Proposed rule for the ESRD Treatment Choices Model: https://www.regulations.gov/document?D=CMS-2019-0101-0001.
Accessed August 28, 2019.
ESRD, end-stage renal disease.
Table 2
Goals and objectives outlined in the July 10, 2019, executive order announcing the
national Advancing American Kidney Health initiativea
Goal
Advancing American Kidney Health: goals and objectives
1
Reduce the risk of kidney failureOBJECTIVE 1: Advance public health surveillance capabilities
and research to improve identification of populations at risk and those in early stages
of kidney diseaseOBJECTIVE 2: Encourage adoption of evidence-based interventions to
delay or stop progression to kidney failure
2
Improve access to and quality of person-centered treatment optionsOBJECTIVE 1: Improve
care coordination and patient education for people living with kidney disease and
their caregivers, enabling more person-centric transitions to safe and effective treatments
for kidney failureOBJECTIVE 2: Introduce new value-based kidney disease payment models
that align health care provider incentives with patient preferences and improve quality
of lifeOBJECTIVE 3: Catalyze the development of innovative therapies including wearable
or implantable artificial kidneys with funding from government, philanthropic, and
private entities through KidneyX and coordinate regulatory and payment policies to
incentivize innovative product development
3
Increase access to kidney transplantsOBJECTIVE 1: Increase the utilization of available
organs from deceased donors by increasing organ recovery and reducing the organ discard
rateOBJECTIVE 2: Increase the number of living donors by removing disincentives to
donation and ensuring appropriate financial support
a
Report by the Health and Human Services Assistant Secretary for Planning and Evaluation:
aspe.hhs.gov/system/files/pdf/262046/AdvancingAmericanKidneyHealth.pdf. Accessed August
28, 2019.
Central components of these plans include both the mandatory ESRD Treatment Choices
model, which will randomly enroll half of US nephrologists and dialysis facilities,
and the voluntary Kidney Care First and Comprehensive Kidney Care Contracting models,
which will build on the existing Comprehensive ESRD Care model. These new payment
models will operate under traditional Medicare (parts A and B) through the Center
for Medicare and Medicaid Innovation. The intent of these payment models is to provide
resources and incentives for the management of patients with CKD stages 4 and 5, use
of home dialysis therapies, and facilitation of kidney transplantation. These models
will be initiated starting on January 1, 2020. Depending on the model, alternative
funding approaches will be implemented in 2020 or 2021 and extend through 2023 or
2026. Cost and clinical outcomes resulting from these models will be evaluated and
decisions will be taken regarding modification or continuation of these new funding
algorithms.
A partial list of additional components of the Advancing American Kidney Health initiative
include deployment of open-source portable electronic care plan tools for patients
with multiple chronic conditions; enhanced education opportunities for patients with
kidney disease; development of new diagnostics and therapies through KidneyX, a public-private
partnership between the US Department of Health and Human Services and the American
Society of Nephrology; new guidance for development of organ preservation technologies;
learning collaborative engagement to reduce kidney discard rates, increase organ recovery,
and accelerate organ placement; research on the use of donors with HIV, hepatitis
C, and the apolipoprotein L1 (APOL1) gene; and expansion of travel, subsistence, and
lost wage reimbursement for potential living kidney donors who are in need of such
assistance to move forward with donation.
Patients with renal disease ultimately may benefit from successful implementation
of the incentives, innovations, and practice-pattern changes that these initiatives
are designed to enhance. However, it is uncertain whether the nephrology community
is resourced and positioned to respond in the short term to many of these new proposed
changes.
Kidney disease is a public health catastrophe. Risk factors for the development and
progression of kidney disease have long been recognized. Despite readily available
and effective treatments, poorly controlled diabetes and hypertension are both causes
and accelerants of renal insufficiency. Furthermore, kidney disease amplifies the
consequences of cardiovascular disease and increases frailty.
1
CKD is associated with increasing mortality to the extent that substantially fewer
Americans have stage 5 than stage 4 CKD, and even fewer have stage 4 when compared
with stage 3 CKD, reflecting in part the high and increasing likelihood of death associated
with progressive renal diseases.
Whereas patients experience few, if any, symptoms until kidney disease is far advanced,
criteria for diagnosing and staging chronic kidney disease are well characterized
and readily available to providers and payers through direct patient contact and by
examination of electronic medical records, laboratory databases, and insurance claims.
2
Yet little has been accomplished previously at national, health system, payer, or
individual practice levels to systematically leverage these data to identify and monitor
patients with CKD or risk factors for CKD and to implement early diagnosis and interventions.
Public education is largely absent.
In the United States, late recognition commonly leads to delayed referrals to nephrologists
and kidney transplant programs; patients and their families are often incompletely
appraised of their options and poorly prepared to choose and begin treatment; and
preparations for renal replacement therapies often are hastily arranged and emergent.
Consequently, most patients with progressive CKD are funneled toward perpetual in-center
hemodialysis.
3
Whereas outcomes in general favor persons who receive early or preemptive kidney transplantation
or may be improved in some respects for persons who initiate peritoneal dialysis or
home hemodialysis, as opposed to in-center hemodialysis, barriers often exist to implementing
these treatment options at the individual patient level, as well as at payer and provider
levels. To the extent that ESRD is a disease that disproportionately affects chronically
ill and elderly persons, not all patients are suitable for transplantation or home
dialysis options. Furthermore, not all patients have social support and the functional
capacity necessary to maintain themselves outside of in-center treatment environments.
A sizeable minority of older patients and, particularly, frail patients with kidney
disease may in fact not benefit from either dialysis or transplantation, instead achieving
better quality and duration of life through supportive therapies. Identifying these
patients is an emerging challenge to providers of kidney disease care.
Workforce, resource, organizational, and financial obstacles facing the Advancing
American Kidney Health initiative are considerable. Although it is possible that implementation
of this initiative eventually may lead to overall cost savings, it is probable that
considerable investment will be needed during the transition from present to future
payment models. Current and prior administrative and financial incentives have led
most nephrologists to concentrate their practices and expertise on either in-center
hemodialysis or on kidney transplantation. Tremendous resources have been invested
in in-center hemodialysis, and interests are entrenched. Historically, payment for
management of CKD has been low, and because nephrologists often are fully committed
to in-center dialysis or transplantation, patients with CKD usually are managed in
primary care settings. Absence of engagement by nephrology professionals in turn leads
to non–evidence-based and inconsistent care, lack of standardization of interventions
to monitor and delay disease progression, failure to engage the patient in choice
of treatment options, and a disorderly transition from CKD to ESRD.
Furthermore, diagnosis and treatment of patients with kidney disease is complex and
frequently requires care during evening and nighttime hours. Nephrologist practice
hours are long, and compensation for nephrologists is less than that of procedure-oriented
medical subspecialties, such as cardiology and gastroenterology. Consequently, nephrology
does not present itself as an attractive career choice to medical students and house
officers. Nephrology fellowship programs no longer attract top-tier trainees, and
many programs have difficulty filling positions or compromise on background and quality
when accepting applicants into their fellowships.
4
Consequently, the United States has a shortage of nephrologists, and many are not
comprehensively trained in all aspects of the management of CKD and ESRD, including
diagnosis of renal and urological diseases, home hemodialysis, in-center hemodialysis,
peritoneal dialysis, transplant medicine, and supportive alternative and palliative
care.
5
Practice settings rarely provide patients with the full range of therapeutic alternatives.
Similarly, nephrology office and dialysis administrators, mid-level providers, nurses,
social workers, dieticians, and patient educators are not trained to provide and support
the full range of CKD and ESRD treatment options. Practices and facilities in US Territories
and in rural, isolated, and highly underserved urban areas are presented with especially
severe barriers to providing comprehensive kidney care alternatives. Developing resources
and training substantial numbers of general nephrologists, staff, and nonphysician
providers to offer the entire list of options that ideally would be available to guarantee
quality comprehensive treatment for patients with CKD and ESRD will be costly and
require investments in personnel and resources and are unlikely to be achieved within
the anticipated time frames of the proposed payment models.
As shown in Goal 3 and the related objectives from Table 2, increasing kidney transplantation
is a critical element of the Advancing American Kidney Health initiatives. Challenges
to increasing kidney transplantation include improving access to the waiting list
and living donor transplantation, optimizing organ availability, and refining allocation
policies.
It is well documented that access to live donation and deceased donor kidney transplant
waiting lists varies across the United States. Similarly, organ procurement organization
performance and transplant center organ acceptance practices are highly variable.
Models developed at previous US Department of Health and Human Services–sponsored
donation and transplantation collaboratives have demonstrated opportunities for sizably
increasing donation and transplantation rates. Adoption of these strategies were compromised
by resource limitations, absence of incentives, distrust of adjustment models used
to rank organ procurement organizations and transplant programs, and fears that utilization
of nontraditional donors might result in unfavorable regulatory organ procurement
organization and transplant center performance reviews.
Increasing living donor kidney transplantation will be necessary to the aim of “doubling
the number of kidneys available for transplantation by 2030.” However, concern for
the well-being of the live donor must be the first and foremost consideration in any
such expansion. In addition to the pain and anxiety associated with the surgery, living
donation is often a financial hardship on the donor and the donor’s family. Expansion
of travel, subsistence, and lost wage reimbursement for potential living kidney donors
who are in need of such assistance to move forward with donation would be an important
contribution to the well-being of many donors and potentially increase opportunities
for transplantation for their loved ones and their intended recipients. Multiple proposals
to ensure and monitor living donor well-being were developed at a 2011 conference
on living donor follow-up. Key among these were calls to fund a scientifically sound,
adequately powered, long-term living donor follow-up study and to provide a mechanism
by which living donors could self-report late complications arising from donation
to the Organ Procurement and Transplantation Network.
6
These recommendations should be revisited and acted upon.
In addition, one of the important developments for promoting living donor transplantation
has been the introduction of kidney paired donation. Adoption of a living donor standard
acquisition charge has been proposed to facilitate and provide cost certainty for
kidney paired donation across payers and institutions.
7
The Centers for Medicare and Medicaid Services should formally institute this payment
mechanism.
After nearly 10 years of intense study and negotiation, a new US deceased donor kidney
allocation system was adopted in December 2014.
8
This system is an important step forward in allocation policy and has reduced barriers
to transplantation for minorities and sensitized transplant candidates. To a limited
extent, it also allows for survival matching between donor kidneys and waitlisted
candidates with the longest potential for posttransplant survival. However, it has
been shown through allocation modeling that, even without increasing the size of the
deceased donor pool, tens of thousands of additional posttransplant life years could
be obtained from alternative kidney allocation systems that allocate kidneys to maximize
incremental posttransplant patient survival.
9
Consideration of alternative allocation systems that improve the survival potential
arising from the deceased donor pool should be reconsidered as efforts focus on increasing
opportunities for transplantation.
In announcing the Advancing American Kidney Health initiative, the administration
emphasized its intent to “shift from paying for sickness and procedures to paying
for health and outcomes.” These proposals reflect input from government agencies,
patients, patient advocates, providers, professional organizations, dialysis entities,
pharmaceutical companies, and device manufacturers. Current funding mechanisms, policies,
and practices in renal medicine are far from ideal and poorly serve the patient, payer,
and physician communities. As previously described, this initiative is likely to face
many challenges, and true reform will require appropriate incentives and new adequately
directed resources both during and after the transition from current to future payment
models. However, altering the current national kidney care model has the potential
to motivate shifts in values, funding, patient care strategies, outcomes, and culture.
This initiative deserves the community’s active engagement, participation, and support.
Disclosure
All the authors declared no competing interests.